MedWatch

Denmark gives four cancer drugs the thumbs-down

Amgen, Astellas, Johnson & Johnson, and Incyte have not made it through the eye of the needle at the Danish Medicines Council, which only recommended a treatment from Bristol Myers Squibb.

Photo: Kim Kyung-Hoon/Reuters/Ritzau Scanpix

At the end of last week, the Danish Medicines Council held a meeting that turned out to be bad news for a lot of companies hoping for a recommendation from experts.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs